Best Worst Case

Chourmouzios Arampatzis MD, PhD, FESC
Disclosure Statement of Financial Interest

- Research Grants
- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Others
Case_1

59y male,
CDRF
- Current smoker
- Dyslipidemia
- Familial history
- Hypertension
Angiography
### J-CTO score for predicting successful guidewire crossing within 30 min

<table>
<thead>
<tr>
<th></th>
<th>OR (95% CI)</th>
<th>b coefficient</th>
<th>point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously failed lesion</td>
<td>0.39 (0.15-0.97)</td>
<td>0.93</td>
<td>1</td>
</tr>
<tr>
<td><strong>Blunt stump type</strong></td>
<td><strong>0.32 (0.18-0.55)</strong></td>
<td><strong>1.14</strong></td>
<td><strong>1</strong></td>
</tr>
<tr>
<td>Bending</td>
<td>0.34 (0.20-0.58)</td>
<td>1.09</td>
<td>1</td>
</tr>
<tr>
<td>Calcification</td>
<td>0.26 (0.15-0.44)</td>
<td>1.36</td>
<td>1</td>
</tr>
<tr>
<td>Occlusion length &gt;20cm</td>
<td>0.19 (0.09-0.39)</td>
<td>1.65</td>
<td>1</td>
</tr>
</tbody>
</table>

*J Am Coll Cardiol Intv. 2011;4(2):213-221*
Right radial
JL 3.5 6F
Pilot, miracle 6
Patient at this point developed VF shock X2 times, SHR. Contrast Load 130ml, Completely stable. Abort or Proceed?
Case_2 Demographics

65y male
On 2009 unprovoked thrombosis of portal and mesenteric vein
Esophageal varices
On anticoagulation (sintrom)
Hct 39.5
WBC 6270
PLT 460,000
## Lab profile

### Thrombophilia Diathesis

<table>
<thead>
<tr>
<th></th>
<th>Value</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithrombin III (ATIII)</td>
<td>101.5%</td>
<td>75-125</td>
</tr>
<tr>
<td>Protein S</td>
<td>128.1%</td>
<td>70-123</td>
</tr>
<tr>
<td>Protein C</td>
<td>116.4%</td>
<td>70-140</td>
</tr>
<tr>
<td>APC-R</td>
<td>3.4</td>
<td>&gt;1.5</td>
</tr>
<tr>
<td>Lupus Anticoagulant</td>
<td>Negative</td>
<td></td>
</tr>
</tbody>
</table>

### Immunological Control

<table>
<thead>
<tr>
<th></th>
<th>Value</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA GPL</td>
<td>1</td>
<td>0-15</td>
</tr>
<tr>
<td>ACA MPL</td>
<td>0-6</td>
<td></td>
</tr>
<tr>
<td>B2 glycoprotein IgA</td>
<td>3.2 U/ml</td>
<td>0.6-6.1</td>
</tr>
<tr>
<td>B2 glycoprotein IgG</td>
<td>3.7 U/ml</td>
<td>0.6-6.1</td>
</tr>
<tr>
<td>B2 glycoprotein IgM</td>
<td>3.3</td>
<td>0.6-6.1</td>
</tr>
</tbody>
</table>

### Hemostasis Gene Control-PCR

- **FV Leiden (G1691A)**: Normal
- **FII (G2021A)**: Heterozygous
- **MTHFR (C677T)**: Heterozygous
- **MTHFR (A1298C)**: Heterozygous
- **JAK-2/ V617VF**: Mutation
CDRF
• Current smoker
• HT
• Dyslipidemia
AR 1, Runthrough
Issues During Primary PCI

**Small Stent**
- Proximal malapposition – Underexpansion
  - Stent thrombosis
  - Restenosis

**Large Stent**
- Distal Overdilatation
  - Dissection perforation
  - No reflow
Why/when Stentys

In specific lesions with

• Significance variance in vessel diameter (aneurysm, ectactic or severe tapering)
• Large vessel diameter (up to 6mm)
• Heavy thrombus load
Myeloproliferative Neoplasms

Stem cell derived disorders in Mutation in either the januskinase of the EPO receptor- (JAK-2) or the calreticulin (CALR) gene are characteristic for the diagnosis. Enhanced proliferation of RBC, WBC and PLT and thus increase the risk for vascular events and transformation to acute myeloid leukemia.

The incident is 6-10/100.000 (0.006%)

- Polycythemia Vera ↓36%
- Essential thrombocytosis ↓32%
- Myelofibrosis ↓79%

<table>
<thead>
<tr>
<th></th>
<th>1-year RSR</th>
<th>5-year</th>
<th>10-year</th>
</tr>
</thead>
<tbody>
<tr>
<td>PV  (95% CI)</td>
<td>0.95 (0.94-0.96)</td>
<td>0.83 (0.81-0.84)</td>
<td>0.64 (0.62-0.67)</td>
</tr>
<tr>
<td>ET  (95% CI)</td>
<td>0.92 (0.90-0.93)</td>
<td>0.80 (0.78-0.82)</td>
<td>0.68 (0.64-0.71)</td>
</tr>
<tr>
<td>PMF (95% CI)</td>
<td>0.76 (0.73-0.79)</td>
<td>0.39 (0.35-0.43)</td>
<td>0.21 (0.18-0.25)</td>
</tr>
</tbody>
</table>

The 2016 revision of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Guidezilla is not a monster
83y male, NSTEMI, Diabetes, HT, dyslipidemia, EF 35%, GFR 48ml/s, 2007 LIMA, VGX2
PCI

Premier 3.5X16mm

Premier 3.0X24mm

Premier 3.5X32mm
Guidezilla is not a monster

48 male cypher
2.75X18 &
3x18mm on 2006